



IBA Dolphin® Patient Treatment QA Solution First Clinical Use In Japan


Innovative Dolphin® system clinically implemented at the Osaka International Cancer Institute, Japan, ensuring safer radiation therapy and more efficient QA workflow

Osaka, May 18, 2017 – IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy quality assurance (QA) for the treatment of cancer, announces the **first clinical implementation of Dolphin patient QA solution in Japan**.

The Radiation Therapy expert team at the Osaka International Cancer Institute has successfully validated and clinically implemented the Dolphin transmission detector system. With the use of **Dolphin**, the team opened a **new area of QA standard for improved efficiency and treatment quality in radiation therapy**. To address the special high demands of SRS and SBRT cases the hospital’s team has clinically implemented Dolphin due to the system’s ability to verify treatment doses in 3D within the patient’s individual anatomy.

“We are proud to provide a new level of treatment quality and safety to all our radiation therapy patients. Dolphin allows us to undertake an intensive quality assurance prior to each patient treatment in the most efficient way. This is the basis to achieve the highest QA standards today and tomorrow” says **Masayoshi Miyazaki, Chief Medical Physicist at Osaka International Cancer Institute, Japan**.

He continues, “compared to our previous table based QA solution we can now measure and verify our patient QA in significantly less time and verify the results in 3D patient individual anatomy. We setup Dolphin on the linac gantry in only one minute”.



About the Dolphin® System

Dolphin is a complete solution that offers a **higher capability to detect and verify possible treatment dose discrepancies** compared to conventional QA solutions, thus contributing to a **more efficient and safer radiation therapy**. This improvement is based on Dolphin’s high treatment dose measurement resolution.

Highly complex IMRT and rotational treatment plans are delivered and measured with the Dolphin transmission detector prior to each patient treatment. A sophisticated TPS-Class software allows **verification of dose deviations in 3D patient anatomy** between the plan and actual delivered dose measured with Dolphin.

Press release | 18/05/2017

IBA | Dosimetry GmbH

Bahnhofstr. 5 | 90592 Schwarzenbruck | Germany | T +49 9128 607 0 | F +49 9128 607-10

Registration Court: Local Court (Amtsgericht) Nürnberg, HRB 4262

Managing Directors (Geschäftsführer): Olivier Legrain, Robby Plompen, Berthold Baldus

Dosimetry-info@iba-group.com | www.iba-dosimetry.com

**PROTECT +
ENHANCE +
SAVE LIVES**



The hospital's **patient QA workflow efficiency** is increased with Dolphin's "plug and play" wireless setup and its automatic verification software displaying instant QA results.

The Dolphin solution including the detector and the software is "online ready" and currently used for pre-treatment QA. The system will be capable of **measuring the actual patient treatment dose in online mode, fraction by fraction**. The online capability is currently pending release.

For more information visit <http://www.iba-dosimetry.com/>

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

Contact:

Ralf Schira

Vice President Marketing

IBA Dosimetry

ralf.schira@iba-dosimetry.com

<http://www.iba-dosimetry.com/>